Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Human Immunodeficiency Virus (HIV)-1 Therapeutics market report explains the definition, types, applications, major countries, and major players of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Genentech Inc (US)
Boehringer Ingelheim GmbH (Germany)
Cipla Inc (India)
Merck & Co Inc (US)
Bristol-Myers Squibb Company (US)
AbbVie Inc(US)
By Type:
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
By End-User:
Hospitals
Clinics
Labs
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Outlook to 2028- Original Forecasts
-
2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market- Recent Developments
-
6.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market News and Developments
-
6.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Deals Landscape
7 Human Immunodeficiency Virus (HIV)-1 Therapeutics Raw Materials and Cost Structure Analysis
-
7.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Raw Materials
-
7.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Price Trend of Key Raw Materials
-
7.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Suppliers of Raw Materials
-
7.4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Rate of Raw Materials
-
7.5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Cost Structure Analysis
-
7.5.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Raw Materials Analysis
-
7.5.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Labor Cost Analysis
-
7.5.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Manufacturing Expenses Analysis
8 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Import and Export Analysis (Top 10 Countries)
-
8.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Export by Region (Top 10 Countries) (2017-2028)
9 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Entry and Fusion Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Protease Inhibitors (PIs) Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Integrase Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Coreceptor Antagonists Consumption and Growth Rate (2017-2022)
-
9.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Labs Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis and Outlook till 2022
-
10.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.2.2 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.2.3 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.2 UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.3 Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.4 Belgium Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.5 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.6 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.7 Denmark Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.8 Finland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.9 Norway Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.10 Sweden Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.11 Poland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.12 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.3.13 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.2 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.3 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.4 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.5 Pakistan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.6 Bangladesh Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.7 Indonesia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.8 Thailand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.9 Singapore Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.10 Malaysia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.11 Philippines Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.4.12 Vietnam Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.5.2 Colombia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.5.3 Chile Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.5.4 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.5.5 Venezuela Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.5.6 Peru Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.5.7 Puerto Rico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.5.8 Ecuador Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.6.2 Kuwait Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.6.3 Oman Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.6.4 Qatar Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.6.5 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.6.6 United Arab Emirates Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.7.2 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.7.3 Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.7.4 Algeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
10.8.2 New Zealand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
11 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Competitive Analysis
-
11.1 Genentech Inc (US)
-
11.1.1 Genentech Inc (US) Company Details
-
11.1.2 Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
11.1.4 Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Boehringer Ingelheim GmbH (Germany)
-
11.2.1 Boehringer Ingelheim GmbH (Germany) Company Details
-
11.2.2 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
11.2.4 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Cipla Inc (India)
-
11.3.1 Cipla Inc (India) Company Details
-
11.3.2 Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
11.3.4 Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Merck & Co Inc (US)
-
11.4.1 Merck & Co Inc (US) Company Details
-
11.4.2 Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
11.4.4 Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Bristol-Myers Squibb Company (US)
-
11.5.1 Bristol-Myers Squibb Company (US) Company Details
-
11.5.2 Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
11.5.4 Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 AbbVie Inc(US)
-
11.6.1 AbbVie Inc(US) Company Details
-
11.6.2 AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
11.6.4 AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
11.6.5 Recent Research and Development Strategies
12 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Outlook by Types and Applications to 2028
-
12.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Entry and Fusion Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Protease Inhibitors (PIs) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Integrase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Coreceptor Antagonists Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Labs Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis and Outlook to 2028
-
13.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.2.2 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.2.3 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.2 UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.3 Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.4 Belgium Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.5 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.6 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.7 Denmark Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.8 Finland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.9 Norway Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.10 Sweden Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.11 Poland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.12 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.3.13 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.2 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.3 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.4 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.8 Thailand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.9 Singapore Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.11 Philippines Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.5.2 Colombia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.5.3 Chile Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.5.4 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.5.6 Peru Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.6.3 Oman Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.6.4 Qatar Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.7.2 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.7.3 Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.7.4 Algeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Human Immunodeficiency Virus (HIV)-1 Therapeutics
-
Figure of Human Immunodeficiency Virus (HIV)-1 Therapeutics Picture
-
Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Consumption and Growth Rate (2017-2022)
-
Figure Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Consumption and Growth Rate (2017-2022)
-
Figure Global Entry and Fusion Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Protease Inhibitors (PIs) Consumption and Growth Rate (2017-2022)
-
Figure Global Integrase Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Coreceptor Antagonists Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Labs Consumption and Growth Rate (2017-2022)
-
Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Country (2017-2022)
-
Table North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Country (2017-2022)
-
Figure United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Country (2017-2022)
-
Figure Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Belgium Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure France Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Denmark Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Finland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Norway Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Sweden Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Poland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Table APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Country (2017-2022)
-
Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Thailand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Singapore Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Philippines Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Table South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Country (2017-2022)
-
Figure Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Colombia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Chile Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Peru Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Table GCC Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Country (2017-2022)
-
Figure Bahrain Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Oman Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Qatar Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Country (2017-2022)
-
Figure Nigeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Algeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Oceania Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Country (2017-2022)
-
Figure Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Genentech Inc (US) Company Details
-
Table Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
Table Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
Table Boehringer Ingelheim GmbH (Germany) Company Details
-
Table Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
Table Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
Table Cipla Inc (India) Company Details
-
Table Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
Table Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
Table Merck & Co Inc (US) Company Details
-
Table Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
Table Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
Table Bristol-Myers Squibb Company (US) Company Details
-
Table Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
Table Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
Table AbbVie Inc(US) Company Details
-
Table AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Main Business and Markets Served
-
Table AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Portfolio
-
Figure Global Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Entry and Fusion Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Protease Inhibitors (PIs) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Integrase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Coreceptor Antagonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Labs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Country (2022-2028)
-
Table North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
